Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 5
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.
von Guggenberg E, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, di Santo G, Virgolini IJ. von Guggenberg E, et al. Among authors: bayerschmidt s. J Nucl Med. 2023 Jun;64(6):859-862. doi: 10.2967/jnumed.122.264977. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657979 Free article.
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning - A retrospective analysis.
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss A, Gruber L, Virgolini IJ. Nilica B, et al. Among authors: bayerschmidt s. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 May-Jun;41(3):138-145. doi: 10.1016/j.remnie.2021.04.007. Epub 2021 Apr 15. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022. PMID: 35577489
Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.
Santo G, Di Santo G, Sviridenko A, Bayerschmidt S, Wirth L, Scherbauer F, Lehmann P, von Guggenberg E, Decristoforo C, Heidegger-Pircher I, Bektic J, Virgolini I. Santo G, et al. Among authors: bayerschmidt s. Eur J Nucl Med Mol Imaging. 2024 Sep 3. doi: 10.1007/s00259-024-06905-5. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39225826
Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.
Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka A, Decristoforo C, di Santo G, von Guggenberg E, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: bayerschmidt s. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):123-133. doi: 10.1007/s00259-020-04846-3. Epub 2020 May 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 32385647
Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: bayerschmidt s. J Nucl Med. 2021 Nov;62(11):1550-1557. doi: 10.2967/jnumed.120.261866. Epub 2021 Mar 12. J Nucl Med. 2021. PMID: 33712533 Free PMC article.
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis.
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L, Virgolini IJ. Nilica B, et al. Among authors: bayerschmidt s. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Aug 9:S2253-654X(21)00062-7. doi: 10.1016/j.remn.2021.03.004. Online ahead of print. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021. PMID: 34384731 English, Spanish.
Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
Bayerschmidt S, Uprimny C, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Bayerschmidt S, et al. Diagnostics (Basel). 2021 Jun 30;11(7):1191. doi: 10.3390/diagnostics11071191. Diagnostics (Basel). 2021. PMID: 34208989 Free PMC article.